PharmaDiagnostics Launches SoPRano(TM) range of Screening Products and Services
News Feb 08, 2010
PharmaDiagnostics NV, a company developing and marketing a broadly-enabling, label-free screening technology that uniquely does not require specialized equipment, announces today the launch of SoPRano(TM), a high-performance set of screening tools to accelerate the drug discovery process for pharmaceutical and biotechnology companies.
SoPRano(TM)'s key advance is to use the proven principle of surface plasmon resonance (SPR) and make it available in high throughput on a standard plate-reader, without the need for costly specialist equipment. PharmaDiagnostics already offers ADME/PK and custom assay development products and services, and is working with leading research groups to introduce regular further platform enhancements in new application areas.
Label-free screening is currently an area of great interest in the pharmaceutical research market. PharmaDiagnostics' approach stands out as all other available label-free technologies require expensive dedicated equipment that restricts both breadth of application and compound throughput. PharmaDiagnostics' localized surface plasmon resonance technology (LSPR) is broadly enabling, with easy to use protocols, and is applicable to a range of assays for both small molecule and antibody screening and characterization. For the first time, label-free screening can be applied in high throughput applications.
"With SoPRano(TM), PharmaDiagnostics is providing label-free screening for a much broader range of researchers," said Dr David Ricketts, CEO at PharmaDiagnostics. "Early customer feedback has been extremely positive. This product launch at Screening Europe and our new corporate website and online SoPRano(TM) facility demonstrates PharmaDiagnostics' commitment to develop and enhance SoPRano(TM) and bring our customers real value."
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Integrated Lead Discovery: An Evolving ToolboxNews
A new SLAS Discovery review article offers an informative guide to the established and emerging tools available for early drug discovery and screening, and provides illustrative scenarios demonstrating considerations that drive decisions on choice of lead discovery tactics.READ MORE